190 related articles for article (PubMed ID: 36017822)
1. ABI2-mediated MEOX2/KLF4-NANOG axis promotes liver cancer stem cell and drives tumour recurrence.
Chen J; Li H; Zhang B; Xiong Z; Jin Z; Chen J; Zheng Y; Zhu X; Zhang S
Liver Int; 2022 Nov; 42(11):2562-2576. PubMed ID: 36017822
[TBL] [Abstract][Full Text] [Related]
2. ZHX2 restricts hepatocellular carcinoma by suppressing stem cell-like traits through KDM2A-mediated H3K36 demethylation.
Lin Q; Wu Z; Yue X; Yu X; Wang Z; Song X; Xu L; He Y; Ge Y; Tan S; Wang T; Song H; Yuan D; Gong Y; Gao L; Liang X; Ma C
EBioMedicine; 2020 Mar; 53():102676. PubMed ID: 32114388
[TBL] [Abstract][Full Text] [Related]
3. CD133
Liu K; Hao M; Ouyang Y; Zheng J; Chen D
Sci Rep; 2017 Jan; 7():41499. PubMed ID: 28134312
[TBL] [Abstract][Full Text] [Related]
4. RACK1 Promotes Self-Renewal and Chemoresistance of Cancer Stem Cells in Human Hepatocellular Carcinoma through Stabilizing Nanog.
Cao J; Zhao M; Liu J; Zhang X; Pei Y; Wang J; Yang X; Shen B; Zhang J
Theranostics; 2019; 9(3):811-828. PubMed ID: 30809310
[TBL] [Abstract][Full Text] [Related]
5. Targeting AMP-activated kinase impacts hepatocellular cancer stem cells induced by long-term treatment with sorafenib.
Bort A; Sánchez BG; Mateos-Gómez PA; Vara-Ciruelos D; Rodríguez-Henche N; Díaz-Laviada I
Mol Oncol; 2019 May; 13(5):1311-1331. PubMed ID: 30959553
[TBL] [Abstract][Full Text] [Related]
6. TARBP2-mediated destabilization of Nanog overcomes sorafenib resistance in hepatocellular carcinoma.
Lai HH; Li CW; Hong CC; Sun HY; Chiu CF; Ou DL; Chen PS
Mol Oncol; 2019 Apr; 13(4):928-945. PubMed ID: 30657254
[TBL] [Abstract][Full Text] [Related]
7. Dual Targeting of Sorafenib-Resistant HCC-Derived Cancer Stem Cells.
Shrestha R; Bridle KR; Cao L; Crawford DHG; Jayachandran A
Curr Oncol; 2021 Jun; 28(3):2150-2172. PubMed ID: 34208001
[TBL] [Abstract][Full Text] [Related]
8. Reciprocal regulation by TLR4 and TGF-β in tumor-initiating stem-like cells.
Chen CL; Tsukamoto H; Liu JC; Kashiwabara C; Feldman D; Sher L; Dooley S; French SW; Mishra L; Petrovic L; Jeong JH; Machida K
J Clin Invest; 2013 Jul; 123(7):2832-49. PubMed ID: 23921128
[TBL] [Abstract][Full Text] [Related]
9. C-terminal truncated hepatitis B virus X protein regulates tumorigenicity, self-renewal and drug resistance via STAT3/Nanog signaling pathway.
Ching RHH; Sze KMF; Lau EYT; Chiu YT; Lee JMF; Ng IOL; Lee TKW
Oncotarget; 2017 Apr; 8(14):23507-23516. PubMed ID: 28186991
[TBL] [Abstract][Full Text] [Related]
10. RAB27A-dependent release of exosomes by liver cancer stem cells induces Nanog expression in their differentiated progenies and confers regorafenib resistance.
Huang H; Hou J; Liu K; Liu Q; Shen L; Liu B; Lu Q; Zhang N; Che L; Li J; Jiang S; Wang B; Wen Q; Hu L; Gao J
J Gastroenterol Hepatol; 2021 Dec; 36(12):3429-3437. PubMed ID: 34258777
[TBL] [Abstract][Full Text] [Related]
11. A Novel Function for KLF4 in Modulating the De-differentiation of EpCAM
Karagonlar ZF; Akbari S; Karabicici M; Sahin E; Avci ST; Ersoy N; Ates KE; Balli T; Karacicek B; Kaplan KN; Celiker C; Atabey N; Erdal E
Cells; 2020 May; 9(5):. PubMed ID: 32408542
[TBL] [Abstract][Full Text] [Related]
12. IFI44L is a novel tumor suppressor in human hepatocellular carcinoma affecting cancer stemness, metastasis, and drug resistance via regulating met/Src signaling pathway.
Huang WC; Tung SL; Chen YL; Chen PM; Chu PY
BMC Cancer; 2018 May; 18(1):609. PubMed ID: 29848298
[TBL] [Abstract][Full Text] [Related]
13. Coexpression of gene Oct4 and Nanog initiates stem cell characteristics in hepatocellular carcinoma and promotes epithelial-mesenchymal transition through activation of Stat3/Snail signaling.
Yin X; Zhang BH; Zheng SS; Gao DM; Qiu SJ; Wu WZ; Ren ZG
J Hematol Oncol; 2015 Mar; 8():23. PubMed ID: 25879771
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic regulation of the DNMT1/MT1G/KLF4/CA9 axis synergises the anticancer effects of sorafenib in hepatocellular carcinoma.
Wei T; Lin R; Fu X; Lu Y; Zhang W; Li Z; Zhang J; Wang H
Pharmacol Res; 2022 Jun; 180():106244. PubMed ID: 35550167
[TBL] [Abstract][Full Text] [Related]
15. Nanog regulates self-renewal of cancer stem cells through the insulin-like growth factor pathway in human hepatocellular carcinoma.
Shan J; Shen J; Liu L; Xia F; Xu C; Duan G; Xu Y; Ma Q; Yang Z; Zhang Q; Ma L; Liu J; Xu S; Yan X; Bie P; Cui Y; Bian XW; Qian C
Hepatology; 2012 Sep; 56(3):1004-14. PubMed ID: 22473773
[TBL] [Abstract][Full Text] [Related]
16. EPHB2 Activates β-Catenin to Enhance Cancer Stem Cell Properties and Drive Sorafenib Resistance in Hepatocellular Carcinoma.
Leung HW; Leung CON; Lau EY; Chung KPS; Mok EH; Lei MML; Leung RWH; Tong M; Keng VW; Ma C; Zhao Q; Ng IOL; Ma S; Lee TK
Cancer Res; 2021 Jun; 81(12):3229-3240. PubMed ID: 33903122
[TBL] [Abstract][Full Text] [Related]
17. Caspase-3-Induced Activation of SREBP2 Drives Drug Resistance via Promotion of Cholesterol Biosynthesis in Hepatocellular Carcinoma.
Mok EHK; Leung CON; Zhou L; Lei MML; Leung HW; Tong M; Wong TL; Lau EYT; Ng IOL; Ding J; Yun JP; Yu J; Zhu HL; Lin CH; Lindholm D; Leung KS; Cybulski JD; Baker DM; Ma S; Lee TKW
Cancer Res; 2022 Sep; 82(17):3102-3115. PubMed ID: 35767704
[TBL] [Abstract][Full Text] [Related]
18. GATA5 inhibits hepatocellular carcinoma cells malignant behaviours by blocking expression of reprogramming genes.
Feng H; Zhu M; Zhang R; Wang Q; Li W; Dong X; Chen Y; Lu Y; Liu K; Lin B; Guo J; Li M
J Cell Mol Med; 2019 Apr; 23(4):2536-2548. PubMed ID: 30672133
[TBL] [Abstract][Full Text] [Related]
19. miR-589-5p inhibits MAP3K8 and suppresses CD90
Zhang X; Jiang P; Shuai L; Chen K; Li Z; Zhang Y; Jiang Y; Li X
J Exp Clin Cancer Res; 2016 Nov; 35(1):176. PubMed ID: 27835990
[TBL] [Abstract][Full Text] [Related]
20. Lenvatinib suppresses cancer stem-like cells in HCC by inhibiting FGFR1-3 signaling, but not FGFR4 signaling.
Shigesawa T; Maehara O; Suda G; Natsuizaka M; Kimura M; Shimazaki T; Yamamoto K; Yamada R; Kitagataya T; Nakamura A; Suzuki K; Ohara M; Kawagishi N; Umemura M; Nakai M; Sho T; Morikawa K; Ogawa K; Ohnishi S; Sugiyama M; Mizokami M; Takeda H; Sakamoto N
Carcinogenesis; 2021 Feb; 42(1):58-69. PubMed ID: 32449510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
